JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma

ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions

(2010) K. Van Roosbroeck et al.   HAEMATOLOGICA

The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases

(2010) Yasumichi Hitoshi et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas

(2009) Cecile Meier et al.   MODERN PATHOLOGY

PAX5/TEL Acts as a Transcriptional Repressor Causing Down-modulation of CD19, Enhances Migration to CXCL12, and Confers Survival Advantage in pre-BI Cells

(2008) G. Fazio et al.   CANCER RESEARCH

The JAK kinase inhibitor CP-690,550 supresses the growth of human polycythemia vera cells carrying the JAK2V617Fmutation

(2008) Taghi Manshouri et al.   CANCER SCIENCE

NovelSSBP2-JAK2fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia

(2008) Jennifer L. Poitras et al.   GENES CHROMOSOMES & CANCER

Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization

(2008) S. Hartmann et al.   HAEMATOLOGICA

Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia

(2008) K Nebral et al.   LEUKEMIA

Kinase Activation and Transformation by NUP214-ABL1 Is Dependent on the Context of the Nuclear Pore

(2008) Kim De Keersmaecker et al.   MOLECULAR CELL

Adenosine Kinase Gene Expression in Human Colorectal Cancer

(2008) S. Giglioni et al.   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS